Alembic Pharma sees domestic business growing in double digits this fiscal
Strong brand recall, an efficient sales force, a growing network of supportive doctors and timely product launches are the key catalysts for this business12-07-2020
12-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), please find enclosed schedule of the institutional investor meetings over video conference / voice over calls. We request you to kindly take the same on record and the same be treated as compliance under the applicable regulations of the SEBI LODR.11-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate have requested the Company for issue of duplicate share certificate. We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.08-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Shareholding for the Period Ended June 30, 2020
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here07-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2020, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record.07-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer07-07-2020
Neutral Alembic Pharmaceuticals; target of Rs 975: Motilal Oswal
Motilal Oswal recommended Neutral rating on Alembic Pharmaceuticals with a target price of Rs 975 in its research report dated July 05, 2020.07-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we enclosed herewith schedule of the institutional investor meetings over video conference / voice over calls. We request you to kindly take the same on record and the same be treated as compliance under the applicable regulations of the SEBI LODR.06-07-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), please find enclosed schedule of the institutional investor meetings over video conference / voice over calls. We request you to kindly take the same on record and the same be treated as compliance under the applicable regulations of the SEBI LODR.04-07-2020
Alembic Pharma gets USFDA nod for generic Doxycycline Hyclate tablets
The company's product is a generic version of Almirall, LLC's Acticlate tablets in the same strengths, Alembic Pharma said in a BSE filing.01-07-2020